



November 14, 2023

To whom it may concern:

Company name: Benefit One Inc.
Representative: Norio Shiraishi, President
(Stock exchange code: 2412 / TSE Prime Market)
Contact point: Kenji Ozaki, Managing Director
(Tel: 03-6830-5141)

Notice Concerning the Revision of Full-year Consolidated Performance
Forecasts for FY03/24

Based on the recent performance trends, etc., we have decided to revise the full-year consolidated performance forecasts for the fiscal year ending March 31, 2024 (FY03/24, April 1, 2023 to March 31, 2024) announced on May 11, 2023 as follows:

1. Revision of the full-year consolidated performance forecasts for FY03/24 (April 1, 2023 to March 31, 2024)

	Sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share
Previous forecasts (A)	Millions of yen 45,450	Millions of yen 10,830	Millions of yen 10,970	Millions of yen 7,300	Yen Sen 46.09
Revised forecasts (B)	44,230	9,800	9,940	6,600	41.66
Change (B-A)	▲ 1,220	▲ 1,030	▲ 1,030	▲ 700	—
Change (%)	▲ 2.7%	▲ 9.5%	▲ 9.4%	▲ 9.6%	—
Reference: Results for the previous year (FY03/23)	42,376	10,484	10,565	7,655	48.29

2. Reasons for the revision

In the full-year consolidated performance forecasts for FY03/24 announced on May 11, 2023, we made forecasts for the COVID-19 vaccination support business with an anticipation of incoming orders from municipalities mainly in the third quarter. However, the environment surrounding the business differs significantly from the initial assumption due to the reduction of municipalities that conduct mass vaccination, the downsizing of vaccination, etc. For this reason, we have revised the performance forecasts related to the business.

In the Employee Benefit Services business, Incentive business, and medical checkups and health guidance services, there has been no major change in our perception of the environment since the beginning of the fiscal year. Since there are variable factors such as sales activities and the level of service use by members, we have made no changes to our full-year projections announced on May 11, 2023, for businesses other than the COVID-19 vaccination support business.

We expect no transaction from the beginning in the COVID-19 vaccination support business from FY03/25, the second year of the Medium-term Management Plan announced on May 11, 2023, and do not include the business in our revenue plan. There is no change to the performance goals for FY03/26, the last fiscal year of the Medium-term Management Plan.

Note: The above forecasts are based on information available as of the date of announcement of this document.

Actual results may differ from the forecasts due to various factors in the future.

End of document

<p>Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.</p>
--